Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Viventia Bio Inc (OQ:VITA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 147 Hamelin St
WINNIPEG MB R3T 3Z1
Tel: N/A
Website: N/A
IR: N/A
Key People
Leslie L. Dan
Executive Chairman of the Board
Stephen A. Hurly
President, Chief Executive Officer, Director
Erick J. Lucera
Chief Financial Officer, Treasurer, Secretary
Glen C. MacDonald
Chief Scientific Officer
Gregory P. Adams
Chief Development Officer
Arthur P. DeCillis
Chief Medical Officer
Business Overview
Viventia Bio Inc is a Canada-based biological company. The Company is a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics. The Company's advanced product candidates, Vicinium and Proxinium, are locally administered TPTs. The Company is engaged in developing next generation oncology therapeutics utilizing the Targeted Protein Therapeutic technology (TPT). The TPTs has been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates. The Company is engaged in designing, engineering, developing and commercializing TPTs to identify and address patients with cancers that has a high unmet medical needs.
Financial Overview
For the six months ended 30 June 2015, Viventia Bio Inc revenues was not reported. Net loss increased 31% to $4.9M. Higher net loss reflects Research and development increase of 52% to $2.8M (expense), Interest Exp-Net of Capitalized Interest increase of 95% to $286K (expense), General and administrative increase of 3% to $1.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.29 to -$0.38.